Idenix Pharmaceuticals, Inc. 60 Hampshire Street Cambridge, Massachusetts 02139Idenix Pharmaceuticals Inc • February 6th, 2009 • Pharmaceutical preparations
STOCK PURCHASE AGREEMENTStock Purchase Agreement • February 6th, 2009 • Idenix Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) dated as of February 4, 2009 (the “Execution Date”) between Idenix Pharmaceuticals, Inc., a company organized under the laws of the State of Delaware with its principal place of business at 60 Hampshire Street, Cambridge, Massachusetts 02139, USA (“Idenix”), and SmithKline Beecham Corporation, doing business as GlaxoSmithKline, a company organized under the laws of the Commonwealth of Pennsylvania, with its principal place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19101 USA (“GSK” and, together with Idenix, the “Parties”).
AMENDMENT NO. 5 TO DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENTDevelopment, License and Commercialization Agreement • February 6th, 2009 • Idenix Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 5 (“Amendment No. 5”) to the Development, License and Commercialization Agreement is made and effective as of the 23 day of January, 2009 (“Amendment Effective Date”) between Idenix Pharmaceuticals, Inc., with offices at 60 Hampshire Street, Cambridge Massachusetts 02139, USA (“Idenix US”), Idenix (Cayman) Limited with offices c/o Walkers SPV Limited, Walker House, Mary Street, George Town, Grand Cayman, Cayman Islands (“Idenix Cayman” and together with Idenix US, “Idenix”) and Novartis Pharma AG with offices at Forum 1, Novartis Campus, 4056 Basel, Switzerland (“Novartis”).
